Intrahepatic cholangiocarcinoma (iCCA) is one of the primary liver cancers and presents with tumor heterogeneity. About 50% of iCCAs comprise actionable mutations, which completely change patient management. In addition, the precise diagnosis of iCCA, including subtype, has become crucial, and pathologists play an important role in this regard. This review focuses on iCCA heterogeneity; looking at different perspectives to guide diagnosis and optimal treatment choice.
Citations
Citations to this article as recorded by
Trends and Disparities in Intrahepatic Cholangiocarcinoma-related Mortality in the United States from 1999 to 2020 Obaid Ur Rehman, Malik Saad Hayat, Muhammad Mukarram Shoaib, Eeman Ahmad, Zain Ali Nadeem, Ahmad Zain Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Imaging findings of intrahepatic cholangiocarcinoma for prognosis
prediction and treatment decision-making: a narrative review Jun Gu Kang, Taek Chung, Dong Kyu Kim, Hyungjin Rhee The Ewha Medical Journal.2024;[Epub] CrossRef